Tissue renin-angiotensin system in myocardial hypertrophy and failure.
about
How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trialRenin-Angiotensin-aldosterone system in diabetes and hypertensionDetermination of an angiotensin II-regulated proteome in primary human kidney cells by stable isotope labeling of amino acids in cell culture (SILAC)Redox regulation, NF-kappaB, and atrial fibrillation.The past, present and future of renin-angiotensin aldosterone system inhibitionAspects of gene polymorphisms in cardiovascular disease: the renin-angiotensin system.Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives.Angiotensin II receptor blockers in the treatment of heart failure.Cardiovascular risk reduction with Renin-Angiotensin aldosterone system blockade.Physiology, genetics, and cardiovascular disease: focus on African Americans.Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals.Angiotensin II type 1 receptor expression in human breast tissues.Valsartan in the treatment of heart attack survivorsTreating patients for cardiovascular protection: combination therapy to achieve complete renin-angiotensin system blockade.Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.Effects of AT1 receptor antagonist therapy in patients with severe heart failure pretreated with angiotensin-converting enzyme inhibitorsRelationship between extent and complexity of coronary artery disease and different left ventricular geometric patterns in patients with coronary artery disease and hypertension.Atrial natriuretic peptides in heart failure: pathophysiological significance, diagnostic and prognostic value.Local renin-angiotensin system contributes to hyperthyroidism-induced cardiac hypertrophy.Insights from animal models of myocardial infarction: do ACE inhibitors limit the structural response?Clinical Trials: The HOPE Trial.Glyceryl trinitrate-induced angiotensin-converting enzyme (ACE) inhibition in healthy volunteers is dependent on ACE genotype.
P2860
Q24793341-6B84D300-5B34-42B7-8860-3A4F4F2446BEQ28308222-F77A2D5C-6B95-43AC-A44C-2EBA4F541261Q28387627-087059D4-EE09-455B-A73C-671543FBBDF8Q33644314-1EBB120E-DD2B-4AA9-BD76-394D639AA673Q34094354-B9F3F707-3021-4728-BBB7-1B7E86768178Q34291477-625A2164-41F3-4118-840B-D80AB2560B3AQ34448373-AC271CA7-1044-4D9F-A420-52E6E0240733Q34943387-C1273E25-D319-4150-8C70-EAE6CCAE083EQ35203083-8744650E-BDC3-4455-A8EB-824F26A8E818Q35741743-9F8B3B76-F764-44E3-B87B-9B40689BE432Q36089390-880A8240-0FF5-4C4B-ACA4-68DC8BE08027Q36431752-3457246F-3B9D-404A-96EB-F7BEB8962AEBQ36744015-7A0D5BF2-0C2C-428F-B839-F945B060A354Q36873154-EAD41276-CD65-4BDA-890D-B4BD2EA5E00CQ36985305-E4EA9A58-2D0A-45CF-AD11-53CAB86F4CB3Q37278552-D614B88F-FEED-4F49-9260-735C52AC765EQ37680567-7827917F-C2B6-446C-9C64-03C4CF598281Q37909469-D4157772-410D-4DDA-8A0A-FB5269039720Q42027850-CBE7361C-04C3-4E33-86EB-7BF2FC805D81Q42578760-A6F7D83F-D04C-4649-B5DF-9E5B6FEF40A2Q44881969-B517726A-8982-42DF-9575-36007701E330Q46931504-C02BA64C-2954-4433-8BF4-186B160AB581
P2860
Tissue renin-angiotensin system in myocardial hypertrophy and failure.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Tissue renin-angiotensin system in myocardial hypertrophy and failure.
@en
type
label
Tissue renin-angiotensin system in myocardial hypertrophy and failure.
@en
prefLabel
Tissue renin-angiotensin system in myocardial hypertrophy and failure.
@en
P1476
Tissue renin-angiotensin system in myocardial hypertrophy and failure.
@en
P2093
P304
P356
10.1001/ARCHINTE.153.8.937
P407
P577
1993-04-01T00:00:00Z